United BioSource Corp. Named Preferred Oncology Clinical Research Partner by RainTree Oncology Services

 United BioSource Corp. Named Preferred Oncology Clinical Research Partner by
                          RainTree Oncology Services

Agreement Will Accelerate Clinical Trial Research and Improve Patient Outcomes

PR Newswire

BLUE BELL, Pa., March 31, 2014

BLUE BELL, Pa., March 31, 2014 /PRNewswire/ -- United BioSource Corp. (UBC), a
subsidiary of Express Scripts (NASDAQ: ESRX), has been named the preferred
oncology clinical research partner by RT Oncology Services Corp. (RainTree),
the nation's leading community oncology alliance. The agreement seeks to
improve patient care by accelerating clinical research in the U.S.

UBC is a market leader in the design and execution of peri- and post-approval
clinical trials and clinical studies. As RainTree's preferred oncology
clinical research partner, UBC will have access to patient data — under
research protocol and with appropriate consent — from RainTree's alliance of
oncologists throughout the U.S. UBC also will partner with RainTree to
administer prospective and retrospective observational studies that will
provide information about the safety and efficacy of medication in daily
clinical use.

By standardizing processes within the RainTree community oncology setting,
leveraging network wide electronic medical records and providing robust
adherence to the principles of good clinical practices, this partnership
drives faster completion of clinical research and provides patients in
nonacademic treatment settings with access to the latest therapies.

Patrick Lindsay, president, UBC, said, "This partnership is at the core of
UBC's distinction in supporting clinical development and optimizing the
experience for the patient, physician, manufacturer and payer as new products
are approved by regulators and introduced to the marketplace.

"We now have an excellent opportunity for community oncologists to gain
experience with new therapies in the same setting where approximately 80
percent of cancer patients are treated. When these same medications are
approved and released more broadly, physicians will already have important
experience with these new therapies."

Jeff Patton, MD, chief medical officer of RainTree, said, "Data gathered by
our alliance of oncologists can provide new insights into patterns of care,
potential risk factors of new therapies and health-related quality of life,
among other components essential to improving patient outcomes. UBC is the
experienced partner we need to design and manage clinical research that
optimizes the quality of the patient care we provide." 

About United BioSource Corp.

United BioSource Corp. (UBC), a subsidiary of Express Scripts Holding Company,
leads the market in providing integrated, comprehensive clinical, safety, and
commercialization services.

UBC brings together renowned scientific research and operations experts with
leading-edge technologies, allowing for the best patient and healthcare
provider experience. Comprehensive, end-to-end services cover product and
patient population characterization during development and market entry, as
well as a focus on the patient experience, safety, and adherence.

Working with Express Scripts' specialty pharmacy and specialty distribution
organizations, UBC is uniquely positioned to seamlessly integrate
best-in-class services throughout the lifecycle of a product. For more
information, visit www.ubc.com, or follow @UBCPharma on Twitter.

About RainTree Oncology Services

RainTree Oncology Services is the nation's leading community oncology
alliance, assisting its member practices in achieving better and more
cost-effective treatment of oncology patients while creating new streams of
revenue for community oncology practices. RainTree Oncology achieves this by
negotiating and administering favorable GPO contracts; by implementing
technology allowing RainTree Oncology members to develop and evaluate pathways
to improve patient care and outcomes while reducing costs to the healthcare
system; and by developing commercial relationships that accelerate innovative
oncology treatments and payer arrangements while optimizing oncology patient
care and advancing the science of oncology.

Media Contact:
Christine Portell, Sr. Manager, Communications
Phone: +1 314-684-5112
Email: cportell@express-scripts.com

SOURCE United BioSource Corp.

Website: http://www.ubc.com
Press spacebar to pause and continue. Press esc to stop.